Approved Risk Evaluation and Mitigation Strategies (REMS)

REMS@FDA

Contact Us | REMS Resources | Get REMS Email Alerts | Reports & Data Files

Alosetron

Shared System REMS

REMS last update: 11/22/2016

Products
Goals
Summary
REMS Materials
Update history

What medicines are included in the REMS?

Product Name	Application Number	Application Holder	Added to REMS	DailyMed Link	FDA Link
alosetron ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 200652	WEST-WARD PHARMS INT	11/22/2016	e91c4a69-2ad5-4e21-a279-9e1302b1a3d3	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=200652
alosetron ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 206647	AMNEAL PHARMS	12/22/2016	ba94ab71-11d7-4ce1-9b21-0b8c6a39e993	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206647
alosetron ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 206113	PAR PHARM INC	02/23/2018	9c359516-2981-4951-a672-ae2aa2cc10e7
alosetron ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 209180	RISING PHARMS	01/14/2019	7a6c2fbb-a76a-497e-8cf2-a6dca8945a9d

What is the purpose of the REMS?

The goals and objectives of the Alosetron REMS Program are to mitigate the risks of ischemic colitis (IC) and serious complications of constipation (CoC) associated with alosetron hydrochloride (hereinafter, referred to as alosetron) by:

Informing prescribers of alosetron about:

the serious risks of IC and serious CoC associated with alosetron the importance of understanding that alosetron should only be used in severely affected diarrhea-predominant irritable bowel syndrome patients for whom the benefits exceed the risks.
the importance of counseling patients about the risks of IC and serious CoC.

Informing patients about the risks of IC and CoC and actions to take should they experience early warning signs and symptoms of these risks.

What do participants need to know?

Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the application holder(s) REMS Website or the approved REMS materials for more information.

View application holder(s) REMS Website

Healthcare Providers who prescribe Alosetron

Receive training provided by the REMS program.
Review the drug’s prescribing information.
Review the educational materials: REMS letter for Healthcare Provider, Prescriber Education Slide Deck, Safety Information Fact Sheet for Prescribers, and Patient Education Sheet. | REMS letter to Healthcare Providers | | Prescriber Education Slide Deck | | Safety Information Fact Sheet for Prescribers | | Patient Education Sheet |
Report the completion of training to the REMS program using the Prescriber Completion of Alosetron REMS program Training Form. | Prescriber Completion of Alosetron REMS Program Training Form |

View additional drug-specific postmarket safety information from the FDA

What materials are included in the REMS?

The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers. For a specific Medication Guide of a product in the Alosetron REMS, see the DailyMed link on the Products tab.

Material Name	Material Name Link
Patient Education Sheet (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/Alosetron_2016-11-22_Patient_Education_Sheet.pdf
Prescriber Completion of Alosetron REMS Program Training Form (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/Alosetron_2016-11-22_Prescriber_Completion_Training_Form.pdf
Prescriber Education Slide Deck (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/Alosetron_2016-11-22_Prescriber_Education_Slide_Deck.pdf
REMS document (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/Alosetron_2016-11-22_REMS_document.pdf
REMS full (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/Alosetron_2016-11-22_REMS_full.pdf
REMS letter to Healthcare Providers (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/Alosetron_2016-11-22_REMS_letter_Healthcare Providers.pdf
REMS website screenshot (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/Alosetron_2016-11-22_REMS_website_screenshot.pdf
Safety Information Fact Sheet for Prescribers (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/Alosetron_2016-11-22_Safety_Information_Fact_Sheet_prescribers.pdf

What updates have been made to the REMS?

Date	Summary of change
11/22/2016	Modified to reflect the inclusion of an additional ANDA into the alosetron REMS.

Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.